spasticity
Neurology · 2008–2026
No submission for this condition has carried consumer input, including the 2 made since the comments facility came into use.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| incobotulinumtoxinA Treatment of moderate to severe spasticity of the lower limb in adults following stroke, traumatic brain injury, or spinal cord injury. | Mar 2026 | Recommended with restriction | unclear |
| baclofen Treatment of severe chronic spasticity of cerebral origin, due to multiple sclerosis, due to spinal cord injury, or due to spinal cord disease, in patients who… | Jul 2017 | Recommended | none received |
| botulinum toxin type A purified neurotoxin complex Treatment of moderate to severe spasticity of the lower limb in ambulatory adults following a stroke as second line therapy when standard management has failed… | Jul 2008 | Not recommended | no section in document |
What the PBS pays
$82M in government benefit over 2024–25, across 378,036 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| botulinum toxin type A | $72.8M |
| baclofen | $6.1M |
| incobotulinumtoxinA | $2.6M |
Registered, not subsidised
Medicines on the ARTG for this condition with no PBAC record at all. Registration and subsidy are separate decisions: a medicine can be legally available in Australia and never have been put to the committee.
| Medicine | On the ARTG since | Registrations |
|---|---|---|
| dantrolene hemiheptahydrateDANTRIUM 20mg powder for injection | 1991 | 3 |
The ARTG export holds current registrations only, so the year is the earliest entry still on the register rather than a first-registration date. The condition here comes from the registered label, which is usually broader than the population a sponsor asks to have subsidised.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.